Clovis Oncology Inc. | Key People and Executives
Paul H. Klingenstein
Independent Director
Patrick J. Mahaffy
President, Chief Executive Officer & Director
Michael James Barrett
Chairman
Jim C. Blair
Independent Director
Brian G. Atwood
Independent Director
Thorlef Spickschen
Independent Director
Edward J. McKinley
Independent Director
Paul H. Klingenstein
Independent Director
Keith T. Flaherty
Independent Director
Ginger L. Graham
Independent Director
Patrick J. Mahaffy
President, Chief Executive Officer & Director
Daniel W. Muehl
Principal Financial Officer & SVP-Finance
Lindsey Rolfe
Chief Medical Officer & Executive VP-Clinical
Gillian C. Ivers-Read
Chief Regulatory Officer & Executive VP
Paul E. Gross
Secretary, Chief Compliance Officer & Senior VP
Corwin Dale Hooks
Chief Commercial Officer & Senior Vice President
Lisa Guiterman
Media Contact
Breanna Burkart
Head-Investor Relations
Anna Sussman
Investor Relations Contact
Ann Bozeman
Senior Vice President-Human Resources
Michael James Barrett
Chairman
Jim C. Blair
Independent Director
Brian G. Atwood
Independent Director
Thorlef Spickschen
Independent Director
Edward J. McKinley
Independent Director
Keith T. Flaherty
Independent Director
Ginger L. Graham
Independent Director
| Address |
5500 Flatiron Parkway
Boulder Colorado 80301
United States
|
|
Employees
|
- |
| Website |
http://www.clovisoncology.com |
| Updated |
07/08/2019 |
| Clovis Oncology, Inc. engages in the acquisition, development, and commercialization of anti-cancer agents. Its marketed product, Rubraca, seeks to treat patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies. It also has product candidates, namely Rociletinib and Lucitanib. |
